We need to keep our eye's peeled on Edgar for new filings. The BoD does not have much time so either a PREM 14A for merger or acquisition or an 8K for a reverse split. If merger or takeover then expect the filing sooner as plenty needs to be completed in the time frame. Expect a slightly later filing if its going to be the reverse split which I would expect to be 1 for 6, which I would expect to be trading at the split affected price from 7/10/2017 at $3.60 or thereabouts.
The only other thing that I could see the BoD doing is licensing the Exosome test and I am not sure if that would be enough to put pps up for long enough to satisfy Nasdaq.
I somewhat agree. However, I would like management to come to us (could be letter from SK) explaining why they think we are undervalued. What is coming that they think will move th share price. If there are real things coming then I am not as concerned about the RS. Also there is no reason to RS 7:1. They just said a RS is not in the interest of the SHs. So if the extension isn't for long enough time and a RS is necessary do it at the minimum split necessary.
News 
Market Data 
Discover 
AI
